Vivani Medical at the H.C. Wainwright Conference
ALAMEDA, Calif. — Vivani Medical, Inc. (NASDAQ: VANI) is excited to announce that CEO Adam Mendelsohn, Ph.D., will be presenting an overview of the company's innovative approaches to treatment at the H.C. Wainwright 27th Annual Global Investment Conference in New York City. This premier event is set to take place over several days with Dr. Mendelsohn's presentation scheduled for the morning of September 10.
Details about the Presentation
During his time at the conference, Dr. Mendelsohn will discuss the company's advancements in miniature drug delivery systems, specifically their revolutionary NanoPortal™ implant technology. This breakthrough aims to tackle the critical issue of medication non-adherence, which afflicts nearly half of patients globally. The conference presentation will cover how these long-acting implants can vastly improve outcomes for patients managing chronic conditions.
Event Overview
Date: September 10
Time: 1:00 PM - 1:30 PM, Eastern Time
Venue: Lotte New York Palace Hotel
Insights into NanoPortal™ Technology
Vivani's flagship product candidate, NPM-139, is an innovative semaglutide implant designed for chronic weight management in obese or overweight patients. Dr. Mendelsohn will elaborate on its anticipated launch in clinical development, slated to begin in the near future pending regulatory approvals.
Benefits of the Long-Acting Implants
The NanoPortal™ technology stands out due to its ability to deliver therapeutic agents steadily over extended durations. This is pivotal for enhancing patient adherence to treatment regimens, thereby improving their overall health outcomes. The innovative approach also circumvents common issues faced by patients using daily or weekly medications, such as tolerability concerns and reduced efficacy. With the potential for a once-yearly dosing regimen, Vivani is transforming how chronic conditions are managed.
Emerging Pipeline and Future Developments
In addition to NPM-139, Vivani is advancing other promising candidates including NPM-115, targeting chronic weight management, and NPM-119 for type-2 diabetes treatment. Each product utilizes the same proprietary technology, aiming to ensure improved adherence and better therapeutic outcomes for patients.
The Importance of Ongoing Research
Medication non-adherence is a significant challenge in healthcare, impacting approximately 50% of patients. By providing long-acting, implantable solutions, Vivani Medical seeks to ensure that patients can consistently benefit from their prescribed treatments. The company's research and development efforts are pivotal in contributing to the future of biopharmaceutical solutions.
Company Overview
Vivani Medical, based in California, employs its proprietary technologies to create biopharmaceutical implants aimed at sustained drug delivery. The company's innovative solutions target challenging medical issues, placing a strong emphasis on improving patient compliance through advanced drug administration methods. CEO Adam Mendelsohn's engagement at the H.C. Wainwright Conference highlights the ongoing commitment of Vivani to transform the landscape of chronic disease management.
Frequently Asked Questions
What will Dr. Mendelsohn present at the conference?
Dr. Mendelsohn will discuss Vivani's innovative drug implants and their benefits for chronic disease management.
What is the significance of the NanoPortal™ technology?
The NanoPortal™ technology allows for long-acting drug delivery, improving patient adherence and health outcomes.
What are Vivani's key product candidates?
Vivani's priority products include NPM-139 for weight management, NPM-115, and NPM-119 for diabetes.
When is the H.C. Wainwright Conference?
The conference is scheduled for September 8-10, with Dr. Mendelsohn's presentation on September 10.
How can I find out more about Vivani Medical?
For further information about the company and its products, you can visit their official website or contact their investor relations team.
